Wonderful News!

The Rockefeller Institute (NYC) has initiated a project to find a cure for FHC (Fibrolamellar Hepatacellular Carcinoma). "DeLiver a Cure" provided seed money to begin this research and Sloan Kettering is also participating by donating personnel.

The person spearheading the research at The Rockefeller Institute has a family member who was recently diagnosed with FHC.  He has been given permission to now redirect all his time and effort to finding a cure for FHC.

The Rockefeller Institute named this project "DeLiver a Cure".

From the inception of our foundation we have been raising funds with the hope of some day finding an individual with the talent and compelling commitment to understand and cure this disease. With that now in place, we have a project that requires our collective ongoing financial support in the form of donations, events & fund raising ideas to "DeLiver a Cure".

For more detailed information on the full scope of what we believe to be the only research currently underway to find a cure for FHC, click the "New Research" link on our site menu. .

For Fibrolamellar Hepatocellular Carcinoma

deLIVER a cure is a non-profit foundation set up to fund research for this rare form of cancer. Fibromalellar Hepatocellular Carcinoma is a rare variant of liver cancer that most often occurs in individuals between the ages of 15 and 25 years of age.  Unlike traditional liver cancer, hepatitis, drug use, and cirrhosis of the liver are not causations of this disease.

Because this disease is so rare, statistics are not readily available; but we are led to believe that the incidence is approximately 200 cases per year worldwide.  There is no successful form of treatment---in certain circumstances surgical resection of the liver can be an answer.

There are not enough patients with this disease to conduct clinical trials. Typically, these patients are not admitted to clinical trials for traditional liver cancer because this disease does not manifest elevated Alpha Feta protein levels as found in all other types of liver cancer and thus is required as a qualifier by the National Cancer Institute which regulates most clinical trials in this country.  Because there have been no clinical trials on these patients, there is no recognized form of chemo or radiation treatment recognized by the FDA.